Myeloma Minute: Drug Approvals, Cancer Parity Act, and More

myelomaMinBanner6.27.19.jpg

| INNOVATION | Latest Research

490x245 fda.png

FDA Approves Selinexor in Relapsed/Refractory Myeloma

On Wednesday, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (XPOVIO™) in combination with dexamethasone for the treatment of relapsed/refractory myeloma. This is great news for myeloma patients, who now have a new, first in class, oral agent available. After a contentious ODAC Committee hearing in March where the vote was 8-to-5 against approval, the FDA was reassured by follow-up data. These data included early results from the phase III BOSTON clinical trial, in which selinexor is combined with VELCADE® (bortezomib) and dexamethasone.

LearnMoreButton.png

| INNOVATION | Latest Research

540x270WritingOnPamphlet.jpg

FDA Approves Darzalex Combination Therapy for Newly Diagnosed Myeloma Patients Who Are Ineligible for Transplant

Last week, the Food and Drug Administration (FDA) approved the use of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The Phase 3 MAIA (MMY3008) clinical study results provided the basis for this approval.

LearnMoreButton.png

| ADVOCACY | Legislation

550x275SmithVid3.jpg

Cancer Drug Parity Discussed at Senate Committee Hearing

On June 26, 2019, the Cancer Drug Parity Act was discussed during the Senate Health, Education, Labor, & Pensions (HELP) Committee markup on S. 1895, the Lower Health Care Costs Act. Before the hearing, the IMF provided the committee with a comment letter on the Lower Health Care Costs Act. In this letter, the IMF highlights many issues that could impact myeloma patients. The letter draws the committee’s attention to the Cancer Drug Parity Act. As background, the Cancer Drug Parity Act will help cancer patients access their medications regardless of whether their drugs are administered by IV in a physician’s office or by pill.

HELP Committee Member, Senator Tina Smith, discussed the Cancer Drug Parity Act at the committee markup. She spoke of the importance of the legislation and urged action on the bill. The IMF Advocacy Team thanks Senator Tina Smith (D-MN) and Sen. Jerry Moran (R-KS) for championing this important issue! This bill could move soon, so please let your Senators know of your support at the link below.

TakeActionButton.png

| EDUCATION | Teleconference

250x250teleconference.jpg

| Education | Seminar

250x250laPFS.jpg

Listen to a Replay of the Post-ASCO/EHA/IMWG teleconference with Dr. Brian G.M. Durie
Register Now for the IMF Patient & Family Seminar in Los Angeles

Dr. Brian G.M. Durie explains what’s new and exciting from the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA), and International Myeloma Working Group Summit (IMWG). In case you missed it, catch the replay now.

On August 23-24, 2019, the IMF will host a Patient & Family Seminar at the Hilton in Universal City (555 Universal Hollywood Drive) in Los Angeles. Choose between two registration packages—either attend Friday’s half-day session and the all-day session Saturday, or attend the Saturday session only. Connect with other patients and caregivers. Together, we can learn, build community, and share our stories.

LearnMoreButton.png

Register Now Button.png

| INSPIRATION | Raffle

Hawaii_call_to_actionV5540x270.jpg

A 10-Day Luxury Hawaiian Oasis Is a Winning Raffle Ticket Away

The IMF is hosting a raffle for you to win a 10-day stay at the Villa Ono Oasis in Hawaii. The dates of this paradise vacation are March 16-26, 2020. The winners of this luxury package will receive:

  • A 10-day stay at the Villa Ono Oasis
  • Business-class Airfare for Two on American Airlines to Kailua-Kona, HI
  • A Dolphin Swim Adventure for Two
  • A Manta Ray Night Snorkel for Two
  • A Scuba Instruction Package for Two

Only 1000 raffle tickets will be sold @ $50 each: Tickets are selling fast. Get yours today! All proceeds will benefit International Myeloma Foundation Research and Programs.

ButtonsGetTickets.png

| INNOVATION | Research Grants

490x245NovisGrant.png

Calling All Researchers: Submit Your Grant Applications

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2020 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for applications is Thursday, August 1, 2019.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox7.3.19.png

CLINICAL TRIALS
EVENTS

Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

August 1, 2019
Brian D. Novis Research Grants
Apply Now!

August 2, 2019
Laughs for Life
Hattiesburg, MS

August 23-24, 2019
IMF Patient & Family Seminar
Los Angeles, CA

September 6, 2019
IMF Patient & Family Seminar
Charlotte, NC

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Celgene Corporation, Genentech, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.